Anastrozole has an association between degree of estrogen suppression and outcomes in early breast cancer and is a ligand for estrogen receptor α.

CONCLUSIONS: This matched case-control clinical study revealed that levels of estrone and estradiol above identified thresholds after six months of adjuvant anastrozole treatment were associated with increased risk of an EBCE. Preclinical laboratory studies revealed that anastrozole, but not exemestane or letrozole, is a ligand for estrogen receptor a. These findings represent potential steps towards individualized anastrozole therapy. PMID: 32098767 [PubMed - as supplied by publisher]
Source: Clinical Cancer Research - Category: Cancer & Oncology Authors: Tags: Clin Cancer Res Source Type: research